Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.74 |
| ▸ | MAG | P20916 | 6/20 | 0.47 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | CD22 | P20273 | 1/20 | 0.43 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.42 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.42 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.42 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108941 | 1.00 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL11936571 | 1.00 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL9253179 | 0.92 | NANP (0.63) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL7066109 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL8489507 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL2742889 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL12108940 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7CD22 | |
| SCHEMBL13125452 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL28161285 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL17029902 | 0.91 | NANP (0.74) | NANPMAGSIGLEC7CD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | AusVir Therapeutics Pty Ltd (AU) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | HAVCR2, ENGASE, DNPEP | NANP 106/4885MAG 1899/4885SIGLEC7 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.